NASDAQ:APRE
Aprea Therapeutics, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
atrinpharma.comipo date
Oct 03, 2019
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Back...Show More
Earnings
Earnings Release in 12 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus